Deciphering the logic of genetic variant interactions in autoimmunity
General Audience Summary
Across the human genome, hundreds of DNA variants have been associated with risk of autoimmune disease, many of which are shared risk factors for a combination of multiple sclerosis (MS), type 1 diabetes (T1D) and systemic lupus erythematosus (SLE). However, the majority of these variants lie outside of gene bodies, in regulatory DNA that has subtle effects on gene expression, which has limited our understanding of the root causes of each disease. Despite distinct symptoms, MS, T1D, and SLE have several overlapping DNA risk elements, suggesting shared underlying mechanisms that may inform development of widely applicable therapeutic strategies.
Our objective is to use genetic clues regarding the origins of MS, T1D, and SLE to overcome existing knowledge gaps and identify drug targets relevant to disease causing pathways. Genetic studies have shown that many of these DNA variants are present in regulatory regions active in a specific immune cell subset called CD4+ T cells. This cell type has been demonstrated to promote inflammation in patients and mediates some of the central features of disease progression. Our studies will focus on revealing changes in CD4+ T cell signaling caused by disease risk variants that might precede disease onset. Additionally, autoimmune disease risk is most strongly conferred by the combination of disease associated variants, although most studies have focused on individual regions of DNA in isolation. We aim to understand how combinations of autoimmune associated DNA variants collectively push CD4+ T cells into a harmful state that promotes inflammation. We will use gene editing technology to program combinations of disease associated variants into human CD4+ T cells for in depth analysis of the key features that drive disease risk. Ultimately, we strive to identify regulators which we can therapeutically target to prevent disease onset and progression. We believe that this work will improve our ability to address the source of dysfunction with therapeutic intervention and tailor strategies to fit specific patient needs.
Scientific Abstract
Genetic studies have identified hundreds of risk loci for autoimmunity, many of which are shared across multiple diseases, suggesting common underlying mechanisms. Despite the prioritization of genetic features, there is still limited insight into how most variants lead to disease, which has restricted the development of therapies specific to the source of dysfunction. The vast majority of common autoimmune associated variants reside within non-coding regions of the genome and are concentrated in CD4+ T cell enhancers. While select variants have been associated with changes in the expression of nearby genes, the downstream effects of non-coding variants that predispose to disease remain unclear. Furthermore, most studies have focused on individual variant effects, while the polygenic nature of autoimmune disease suggests that pathogenicity is acquired by the combined effects of many variants. Statistical limitations have hindered the extrapolation of information about pairs or sets of DNA variants from the human population. We aim to overcome this limitation with functional genomics to define the influence of combined non-coding autoimmune disease variants on T cell identity and function. We hypothesize that distinct combinations of non-coding autoimmune disease variants converge on and cooperatively reprogram key signaling pathways in CD4+ T cells to initiate disease relevant dysfunction. Comprehensively, we seek to define convergent molecular changes influenced by combinations of autoimmune disease variants. Informed by the underlying gene networks influencing MS, T1D and SLE risk, we will prioritize intervention strategies specific to the source of cellular dysfunction. We will seek both novel molecular targets as well as minimal genetic signatures for improved existing drug stratification across indications, in an effort to open the door for future therapeutic studies centered around the genetic origins of disease.